Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMP4297 in BRCA-mutated advanced ovarian cancer
NCT04089189Phase 2Completed
- Sponsor
- IMPACT Therapeutics
- Start
- Oct 2019
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of senaparib in ovarian cancer, sponsored by IMPACT Therapeutics. Started Oct 2019; status: completed.
02
Drugs
senaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04089189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04089189.